Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Lutris Pharma logo — Improving Anti-Cancer Therapy by Reducing Dose-Limiting Side...

Lutris Pharma

Improving Anti-Cancer Therapy by Reducing Dose-Limiting Side Effects

Founded 2015 Israel Israel 4 employees Grant Biotechnology, Health Care +1

General Information

Company Name Lutris Pharma
Founded Year 2015
Location Israel Israel
Employees 4
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Lutris Pharma. To contact Lutris Pharma, visit lutris-pharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Lutris Pharma compare?

A PDF of Lutris Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Lutris Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Lutris Pharma

Lutris Pharma is a clinical stage biopharmaceutical company based in Israel. Their mission is to enhance the effectiveness and improve the quality of life for cancer patients undergoing treatment with EGFR inhibitors or radiation, where dermal toxicity often leads to reduced therapy compliance. The company’s focus is on providing novel topical therapies to mitigate these side effects. Their lead asset, LUT014, a topical B-Raf Inhibitor, is currently in phase 2 clinical trial for metastatic colorectal cancer patients with EGFR inhibitor-induced acneiform lesions and a phase 1/2 study for the treatment of radiation-induced dermatitis. Since its establishment in 2015, Lutris Pharma has been operating within the Biotechnology, Health Care, and Health and Wellness industries. As of now, there is no public information available regarding their last investment or the associated investors. Lutris Pharma’s slogan summarizes their core focus: "Improving Anti-Cancer Therapy by Reducing Dose-Limiting Side Effects."

No funding data available for Lutris Pharma yet.

Lutris Pharma Alternatives & Competitors

Lutris Pharma vs
Bicara Therapeutics
Bicara Therapeutics United States

Pioneering bifunctional antibodies for targeted tumor modulation

IPO
123 employees
Biopharma, Biotechnology
Lutris Pharma vs
AbilityPharma
AbilityPharma Spain

Advancing cancer treatment through innovative therapeutics targeting cell membranes.

Venture round
23 employees
Biotechnology, Health Care

FAQ About Lutris Pharma

Improving Anti-Cancer Therapy by Reducing Dose-Limiting Side Effects
Lutris Pharma was founded in 2015.
Lutris Pharma is headquartered in Israel.
Lutris Pharma operates in Biotechnology, Health Care and Health and Wellness.
Lutris Pharma has approximately 4 employees.
Top alternatives and competitors to Lutris Pharma include Bicara Therapeutics, AbilityPharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lutris Pharma and Bicara Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Lutris Pharma, https://bouncewatch.com/company/lutris-pharma, updated 23 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout